This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

This is a phase IV single-arm study prospectively evaluating the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The study found that during the 6 month evaluation no patients experienced major hemorrhagic events, MI, stroke, or death. Three patients did have non-major events that were medically managed and one patient discontinued therapy because of an allergic reaction to apixaban.

This study looked at 21 acute myeloid leukemia patients who had received a hematopoietic cell transplant and experienced relapsed disease. Each patient underwent salvage therapy with a venetoclax- based treatment regimen. Nineteen patients were assessed for treatment response and 12 of the 19 patients responded to venetoclax-based salvage therapy, leading to a 63.2% response rate.

Immunomodulatory therapies for multiple myeloma can increase patient risk for venous thromboembolism (VTE). This phase IV single-arm study assessed the rate of symptomatic VTE over 6 months in 50 patients with multiple myeloma receiving immunomodulatory therapy and apixaban for primary prevention. No patients experienced symptomatic VTE or a major hemorrhage and 3 patients experienced clinically relevant non-major hemorrhage but were able to resume apixaban after medical management.

In this study, we conducted a quality improvement initiative to increase the number of patients taking standard of care maintenance therapies, including cystic fibrosis transmembrane receptor (CFTR) modulators. With implementation of a specialty pharmacist directed protocol, rate of standard of care medication use increased for all therapies. The highest rate of increase was in CFTR modulator use.

In this case series, we discuss 7 males between 17 and 39 years of age who reported testicular pain or discomfort within the first two weeks of starting therapy. The precise mechanism of this side effect is unknown, but it may be related to restoration of CFTR function in the male reproductive tract. All patients experienced resolution of this side effect within a week after onset, regardless of the management, exception for one patient.

The objective of this study was to evaluate the implementation of a dashboard to prevent therapy gaps by prospectively identifying patients on biologic therapy needing a new prescription with outdated labs. The new dashboard was highly effective at reducing the number of patients with a therapy gap, number of gap days, and days to receipt of a new prescription. Pharmacists and nurses reported high satisfaction rates with the new dashboard.

Adherence and persistence to specialty medications can be challenging during transitions in sites of care, provider types, specialty medications, and financial coverage changes. In this report, we review obstacles encountered within these transitions and the role of the specialty pharmacist in overcoming obstacles. Case examples for each type of specialty transition provide insight into the unique complexities faced by patients and shed light on pharmacists’ vital role in patient care.

Sorafenib and regorafenib are oral multikinase inhibitors used to treat some cancers, but adverse events for both drugs are common and often cause patients to discontinue therapy or reduce their dose within several months of initiating therapy. This study found that a pharmacist-initiated tailored intervention reduced sorafenib and regorafenib discontinuations (29% to 13%) and dose reductions due to adverse reactions (18% to 13%).

This study evaluated rates of adherence to biologic DMARDS, measured by proportion of days covered (PDC), across 20 health-system specialty pharmacies through the Health-System Specialty Pharmacy Outcomes Research Consortium. The final median PDC after accounting for appropriate gaps in therapy was high at 95% (IQR, 0.87-0.99), demonstrating the benefits of health-system specialty pharmacies in helping patients with RA remain on effective therapies.